Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib monotherapy in Japanese patients with advanced solid malignancies
NCT05469919Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceralasertib in solid tumor (advanced stage), sponsored by AstraZeneca. Primary endpoints: Dose-Limiting Toxicity at Cycle 1 and Safety and Tolerability (Adverse Events). Started Jun 2022; status: completed.
02
Drugs
ceralasertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05469919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469919.